Several studies have found that there is a correlation between early reduction in ctDNA‐levels and therapeutic efficacy in NSCLC patients treated with anti‐PD‐1/PD‐L1‐therapy [17, 25, 27, 28, 29, 30, 31, 32]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.